Eight-Hour Time-Restricted Feeding: A Strong Candidate Diet Protocol for First-Line Therapy in Polycystic Ovary Syndrome

We aimed to investigate the effects of a 6-week program of 8 h time-restricted feeding (TRF) diet in polycystic ovary syndrome (PCOS), as determined by anthropometric, hormonal, metabolic profiles, and fecal calprotectin level. Thirty women diagnosed with PCOS underwent a 6-week 8 h TRF diet interve...

Full description

Bibliographic Details
Main Authors: Bihter Senem Feyzioglu, Cenk Mustafa Güven, Zerrin Avul
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Nutrients
Subjects:
Online Access:https://www.mdpi.com/2072-6643/15/10/2260
Description
Summary:We aimed to investigate the effects of a 6-week program of 8 h time-restricted feeding (TRF) diet in polycystic ovary syndrome (PCOS), as determined by anthropometric, hormonal, metabolic profiles, and fecal calprotectin level. Thirty women diagnosed with PCOS underwent a 6-week 8 h TRF diet intervention. Age, anthropometric features (body mass index (BMI), waist-to-hip ratio (WHR)) and biochemical results were recorded. Free androgen index (FAI, defining hyperandrogenism) and the homeostatic model assessment-insulin resistance (HOMA-IR) were calculated. Baseline (pre-diet) and 6-week post-diet findings were compared. Mean age was 25.57 ± 2.67 years. BMI (<i>p</i> < 0.001) and WHR (<i>p</i> = 0.001) were found to have significantly decreased after the diet, as well as the percentage of patients defined to have hyperandrogenism (<i>p</i> = 0.016). Reproductive hormone levels, FAI (<i>p</i> < 0.001) and HOMA-IR (<i>p</i> < 0.001) were improved significantly. Metabolic parameters associated with glucose and lipid profiles were also significantly improved after the diet. Additionally, fecal calprotectin levels demonstrated a significant decrease from pre-diet to post-diet (<i>p</i> < 0.001). In conclusion, a 6-week diet intervention with 8 h TRF may be a suitable and effective intermittent fasting protocol that can be used as a first-line option in PCOS.
ISSN:2072-6643